
GYRE
Healthcare · Biotechnology · $471.7M market cap
$4.31+0.01 (+0.2%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +59.8% over 90 days · 30-day revisions 1 up, 2 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 5, 2026 | After the close | -0.15 | 0.04 | +126.7% |
| Aug 7, 2026 | Time not confirmed | -0.08 | -0.12 | -50.0% |
| May 7, 2026 | Before the open | -0.07 | -0.10 | -42.9% |
| Mar 31, 2026 | Time not confirmed | 0.05 | 0.05 | +0.2% |
| Nov 7, 2025 | Before the open | -0.02 | 0.03 | +250.0% |
| Aug 11, 2025 | After the close | 0.03 | 0.00 | -92.7% |
| May 9, 2025 | Before the open | 0.03 | 0.00 | -85.7% |
| Mar 24, 2025 | Before the open | 0.04 | -0.00 | -102.8% |
| Nov 4, 2024 | After the close | — | 0.01 | — |
| Aug 12, 2024 | Before the open | — | 0.03 | — |
| May 9, 2024 | After the close | — | 0.03 | — |
| Mar 27, 2024 | Time not confirmed | -0.60 | 0.00 | +100.0% |
| Oct 26, 2023 | After the close | -0.75 | -1.05 | -40.0% |
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of…
| Aug 3, 2023 | Time not confirmed | -0.07 | -1.05 | -1400.0% |
| May 4, 2023 | Time not confirmed | -0.07 | 0.15 | +314.3% |
| Mar 9, 2023 | Time not confirmed | -0.10 | -19.05 | -18042.9% |
| Nov 23, 2022 | Time not confirmed | -0.10 | -2.40 | -2300.0% |
| Aug 15, 2022 | Time not confirmed | -0.24 | 24.60 | +10140.8% |
| May 9, 2022 | Time not confirmed | -0.46 | -6.90 | -1410.8% |
| Mar 31, 2022 | Time not confirmed | -0.59 | -9.75 | -1559.6% |
| Nov 12, 2021 | Time not confirmed | -0.66 | -12.00 | -1718.2% |
| Aug 5, 2021 | Time not confirmed | -0.69 | -9.60 | -1281.3% |
| May 6, 2021 | Time not confirmed | -0.58 | -11.85 | -1951.9% |
| Mar 4, 2021 | Time not confirmed | -0.86 | -12.90 | -1395.7% |
| Nov 5, 2020 | Time not confirmed | -0.81 | -10.95 | -1257.4% |
| Aug 6, 2020 | Time not confirmed | -0.86 | -14.40 | -1574.4% |
| May 11, 2020 | Time not confirmed | -0.37 | -4.20 | -1035.1% |
| Feb 20, 2020 | Time not confirmed | 0.17 | -18.45 | -10952.9% |
| Nov 7, 2019 | Time not confirmed | -1.16 | -15.90 | -1270.7% |
| Aug 1, 2019 | Time not confirmed | -1.11 | -17.25 | -1454.1% |
| May 2, 2019 | Time not confirmed | -1.08 | -18.90 | -1650.0% |
| Mar 7, 2019 | Time not confirmed | -0.75 | -13.65 | -1720.0% |
| Nov 1, 2018 | Time not confirmed | -0.59 | -9.60 | -1527.1% |
| Aug 2, 2018 | Time not confirmed | -0.62 | -8.10 | -1206.5% |
| May 3, 2018 | Time not confirmed | -0.92 | -8.40 | -813.0% |
| Mar 1, 2018 | Time not confirmed | -1.53 | -1.25 | +18.3% |